导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.06% | 1446/4773 |
| 近一周 | -2.46% | 2241/5462 |
| 近一月 | -4.69% | 2655/5421 |
| 近一季 | -8.58% | 2858/5209 |
| 近半年 | -6.10% | 3012/4920 |
| 近一年 | 7.37% | 1317/4366 |
| 近两年 | 68.95% | 993/2954 |
| 近三年 | 35.28% | 856/2253 |
| 成立以来 | 55.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.93% 1132/4961 |
18.53% 1366/5312 |
- - |
- - |
| 2025 | 30.71% 1298/4813 |
2.10% 1464/3635 |
2.04% 1930/4076 |
24.77% 1437/4524 |
0.55% 1946/4813 |
| 2024 | 5.26% 1843/3463 |
-2.79% 1432/2808 |
-5.07% 1635/3014 |
15.38% 1728/3129 |
-1.14% 1601/3463 |
| 2023 | -5.20% 721/2656 |
7.51% 563/2280 |
-3.90% 956/2385 |
-4.05% 1051/2515 |
-4.37% 987/2655 |
| 2022 | -17.52% 602/2207 |
-13.17% 708/1919 |
3.43% 1156/2016 |
-10.46% 407/2113 |
2.57% 895/2208 |
| 2021 | 20.61% 179/1822 |
-1.01% 416/1255 |
10.98% 412/1330 |
6.18% 240/1466 |
3.40% 440/1822 |
| 2020 | 27.99% 569/1250 |
-3.60% 311/1028 |
15.56% 487/1067 |
10.88% 501/1164 |
3.61% 900/1184 |
| 2019 | 27.87% 529/1092 |
31.01% 218/754 |
-9.24% 641/804 |
0.79% 464/850 |
6.70% 566/918 |
| 2018 | -29.82% 456/834 |
- - |
- - |
- - |
-11.86% 370/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证500指数(LOF)A VS. 长安沪深300非周期A(740101) |